Literature DB >> 17388799

In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.

G T Gerotziafas, I Elalamy, F Depasse, E Perzborn, M M Samama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17388799     DOI： 10.1111/j.1538-7836.2007.02429.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  34 in total

Review 1.  The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.

Authors:  Elisabeth Perzborn; Susanne Roehrig; Alexander Straub; Dagmar Kubitza; Frank Misselwitz
Journal:  Nat Rev Drug Discov       Date:  2010-12-17       Impact factor: 84.694

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.

Authors:  Bethany T Samuelson; Adam Cuker; Deborah M Siegal; Mark Crowther; David A Garcia
Journal:  Chest       Date:  2016-09-13       Impact factor: 9.410

Review 4.  Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.

Authors:  Jochen Graff; Sebastian Harder
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

Review 5.  Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.

Authors:  Bengt I Eriksson; Daniel J Quinlan; Jeffrey I Weitz
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 6.  Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.

Authors:  Celeste B Burness; Caroline M Perry
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

Review 7.  Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.

Authors:  Sebastian Harder; Jochen Graff
Journal:  Eur J Clin Pharmacol       Date:  2013-04-26       Impact factor: 2.953

Review 8.  Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Authors:  Natalie J Carter; Greg L Plosker
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

Review 9.  Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Authors:  Sean T Duggan; Lesley J Scott; Greg L Plosker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation.

Authors:  Saartje Bloemen; H Coenraad Hemker; Raed Al Dieri
Journal:  Haematologica       Date:  2012-10-25       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.